Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is ...

Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

MarketWatch Sep 26, 2024, 10:49:00 PM ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nearly two dozen state geological surveys depend heavily on federal funds. A proposed budget cut could slow or stop key geologic mapping work. By Rebecca Dzombak Using crowdsourced data from ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

The Trump administration announced its decision to maintain a fuel policy change initiated under the Biden administration, aimed at increasing sales of corn-based ethanol. Despite concerns from ...